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Synthesis and evaluation of new polynuclear
organometallic Ru(II), Rh(III) and Ir(III) pyridyl
ester complexes as in vitro antiparasitic and
antitumor agents†
Prinessa Chellan,a Kirkwood M. Land,b Ajit Shokar,b Aaron Au,b Seung Hwan An,b
Dale Taylor,c Peter J. Smith,c Tina Riedel,d Paul J. Dyson,d Kelly Chibalea and
Gregory S. Smith*a
New polynuclear organometallic Platinum Group Metal (PGM) complexes containing di- and tripyridyl
ester ligands have been synthesised and characterised using analytical and spectroscopic techniques
including 1H, 13C NMR and infrared spectroscopy. Reaction of these polypyridyl ester ligands with either
[Ru(p-cymene)Cl2]2, [Rh(C5Me5)Cl2]2 or [Ir(C5Me5)Cl2]2 dimers yielded the corresponding di- or trinuclear
organometallic complexes. The polyaromatic ester ligands act as monodentate donors to each metal
centre and this coordination mode was conﬁrmed upon elucidation of the molecular structures for two
of the dinuclear complexes. The di- and trinuclear PGM complexes synthesized were evaluated for inhi-
bitory eﬀects on the human protozoal parasites Plasmodium falciparum strain NF54 (chloroquine sensitive),
Trichomonas vaginalis strain G3 and the human ovarian cancer cell lines, A2780 (cisplatin-sensitive) and
A2780cisR (cisplatin-resistant) cell lines. All of the complexes were observed to have moderate to high
antiplasmodial activities and the compounds with the best activities were evaluated for their ability to
inhibit formation of synthetic hemozoin in a cell free medium. The in vitro antitumor evaluation of these
complexes revealed that the trinuclear pyridyl ester complexes demonstrated moderate activities against
the two tumor cell lines and were also less toxic to model non-tumorous cells.
Introduction
The aromatic ester functionality is widely used in medicinal
chemistry as aromatic esters tend to be highly lipophilic thereby
enhancing the diﬀusion of the drug across cell membranes.1,2
There are numerous examples of aromatic esters with a variety
of bioactivities described in the literature. As examples, a series
of lipophilic esters prepared from 4-acetyl-2-(2-hydroxyethyl)-5,6-
bis(4-chlorophenyl)-2H-pyridazin-3-one (I, Fig. 1) show in vivo
eﬃcacy as antihypertensive agents,3 a library of aromatic esters
derived from cinnamic acid (II) have demonstrated anti-inflam-
matory eﬀects in vitro4 and ester functionalised analogues of
bezafibrate (III) have also been investigated as orally active hypo-
lipidemic agents.5 Tyrosyl (2-(4-hydroxyphenyl)ethanol) is a
known antioxidant and its ester derivatives have been assessed
as antimicrobial and antileishmanial agents.6
The pyridyl ester containing compound MS-275 (IV) is cur-
rently undergoing phase II clinical trials for malignant mela-
nomas and in combination with retinoic acid for solid tumors
and lymphomas.7 Larger polyester scaﬀolds have also gained
considerable attention for tumor targeting either as micelles
or via conjugation of the potential drug molecule onto the
polyester scaﬀold.8–12 Polyester dendrimers tend to be less
toxic and exhibit better biodegradability compared to poly-
amine and polyamide derivatives.13 Thus, the premise of these
studies is that these macromolecular scaﬀolds act as drug
delivery vehicles, allowing preferential uptake by tumors
through endocytosis. Once in the tumor cell, the ester bonds
are hydrolyzed by esterases and the active drug moieties are
released.
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Mono- and polynuclear ruthenium–arene and pentamethyl-
cyclopentadienyl rhodium and iridium pyridyl complexes show
promising pharmacological activities, particularly as antipro-
liferative agents, making them viable candidates for further
study.14–18 There have been several reports of the conjugation
of the ruthenium arene moieties to mono- and di-aryl esters to
give antitumoral agents with encouraging activities. An etha-
crynic acid derivatized ruthenium–arene complex (V, Fig. 2)
was found to inhibit glutathione-S-transferases with an activity
that was better than the free acid while the simple p-cymene
complex was completely inactive.19–21 Mono- and dipyridyl
ester containing ruthenium arene complexes (VI and VII) have
demonstrated similar in vitro activities against both the cispla-
tin sensitive (A2780) and resistant (A2780cisR) human ovarian
tumor cell lines.22 The pyridyl ester containing complex,
5-fluorouracil-1-methyl isonicotinate ruthenium arene (VIII),
showed a moderate increase in activity against human
BEL-7402 hepatocellular carcinoma cells compared to
5-fluorouracil.14
As antiparasitics, the use of metals from the platinum
group series is gaining rapid attention due to the pioneering
work done by Sánchez-Delgado et al. They reported that a
[Ru(II)–chloroquine]2 dimer and a mononuclear Rh(I)–chloroquine
complex proved active against P. falciparum strains in vitro.23
Fig. 1 Examples of aromatic ester derivatives (I, IV) and ester precursors (II, III) studied for diﬀerent bioactivities.
Fig. 2 Examples of ruthenium arene ester complexes studied for activity as in vitro antitumor agents.
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The dinuclear ruthenium complex is 4.5 times more active
than chloroquine diphosphate against two chloroquine resist-
ant P. falciparum strains, FcB1 and FcB2. The rhodium
complex exhibited activities similar to chloroquine dipho-
sphate. Ruthenium–arene chloroquine conjugates have been
extensively studied for their in vitro antiplasmodial activity
against three chloroquine resistant (W2, Dd2 and K1) and four
chloroquine sensitive (FcB1, 3D7, PFB and F32) P. falciparum
strains.24 Iridium–chloroquine analogues have also shown
activity in the nanomolar range on cultures of P. berghei.25
Since then, the application of PGM complexes as antiparasitic
agents has emerged as a viable area of drug discovery.26–29
In this study, the synthesis and characterisation of a series
of di- and tripyridyl aromatic ester organometallic complexes
containing Ru(II), Rh(III) and Ir(III) are described. The rationale
for the use of these ligands is to increase the lipophilic nature
of the complexes by having multiple ester functionalities. Fur-
thermore, these complexes couple the established in vitro
pharmacological activities of half-sandwich Ru(II), Rh(III) and
Ir(III) moieties with that of alkyl-pyridines. All of the com-
pounds synthesized have been evaluated in vitro as antitumor
agents against the A2780 (cisplatin-sensitive) and A2780cisR
(cisplatin-resistant) human ovarian carcinoma cell lines as well
as antiparasitic agents against P. falciparum strain NF54 (chloro-
quine sensitive) and T. vaginalis strain G3.
Results and discussion
Synthesis
The ligands, diisonicotinic acid 1,4-xylylene diester (1) and
benzene-1,3,5-tricarboxylic acid tripyridin-4-ylmethyl ester (2),
were reacted with the dimeric precursors, [Ru(p-cymene)Cl2]2,
[Rh(C5Me5)Cl2]2 or [Ir(C5Me5)Cl2]2, to yield the corresponding di-
or trinuclear complexes 3–8 (Schemes 1 and 2) in moderate to
high yields. All of the complexes were prepared using the same
general method. The appropriate ligand and dimer were
stirred in DCM at room temperature for 16 hours and the
resulting product was precipitated from the reaction solution
using diethyl ether.
Complexes 3–8 were fully characterized using analytical and
spectroscopic techniques and the structures of 4 and 5 were
established in the solid state by X-ray crystallography. Spectro-
scopic evidence confirming metalation of ligands 1 and 2
via the pyridyl nitrogens was obtained using NMR and IR
spectroscopy.
The proton NMR spectra for complexes 3–8 all show a
downfield shift of the protons ortho to nitrogen compared to
their corresponding free ligands, which is typical for mono-
dentate 4-pyridyl ligands coordinated to Ru(II), Rh(III) or Ir(III)
metal centers.14,16,30–37 This deshielding is expected upon
metal coordination to the nitrogen as it leads to less electron
density in the ortho carbon–hydrogen bond due to strong
back-bonding between an empty π*-orbital of nitrogen and a
filled d-orbital of the transition metal.
In the dinuclear complexes (3–5) this deshielding of the
doublet associated with the ortho protons of the pyridyl ring is
much more pronounced compared to the trinuclear complexes
6–8. This can be attributed to the ester functionalities that are
bonded in the para position of the pyridyl rings giving rise to a
much higher electron withdrawing eﬀect on the ortho protons
compared to complexes 6–8 where the coordinated ligand 2
has a methylene (CH2) spacer separating the ester functional-
ities from the pyridyl rings. For all of the complexes (3–8), the
Scheme 1
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resonances assigned to the ester methylene protons display
minimal changes compared to the free ligands confirming that
no metal coordination occurs to the oxygen atoms.
For the di- and tri-ruthenium complexes, 3 and 6, the
p-cymene ligand displays proton resonances characteristic
of similar neutral piano-stool dichlorido ruthenium
complexes.16,30,33,35–37 The methyl protons of the isopropyl
group are observed at ca. 1.30 ppm, resonating as a doublet
and the protons of the methyl substituent resonate as a singlet
at 2.10 ppm. The aromatic protons of the p-cymene ligand reso-
nate as two doublets between 5.00 and 5.50 ppm. The methyl
protons of the pentamethylcyclopentadienyl ligands of the
rhodium (4 and 7) and iridium (5 and 8) complexes are seen
as a singlet between 1.50 and 1.60 ppm in the proton NMR
spectra for these complexes.
Analysis of complexes 3–8 using 13C{1H} NMR spectroscopy
reveals a high frequency shift of the resonance assigned to the
carbon ortho to nitrogen in the pyridyl ring compared to the
free ligand (observed at ca. 150.0 ppm for 1 and 2) confirming
metal coordination to the pyridyl nitrogens. For complexes
3–5, a shift downfield of approximately 5.0 ppm is noted com-
pared to 1. In comparison to the free ligand 2, a shift of
approximately 5.0 ppm for the ortho carbon is observed for the
tri-ruthenium complex 6 and around 3.0 ppm for the rhodium
and iridium analogues (7 and 8).
Similar to the proton NMR spectra for complexes 3–8, little
to no eﬀect is observed on the other carbon resonances
assigned to the metal-coordinated ester ligands. The reso-
nances assigned to the carbonyl carbon as well as the alkyl ester
carbon occur at approximately the same shift compared to the
free ligand. This serves as further evidence that coordination
to the ester oxygen atoms does not occur.
For the rhodium (4 and 7) and iridium (5 and 8) complexes,
the carbon resonance associated with the methyl substituents
of the pentamethylcyclopentadienyl ligand are observed
between 8.5 and 9.0 ppm. The aromatic carbons of the ring
are observed at approximately 95.0 ppm for the rhodium com-
plexes and in the iridium complexes these carbons resonate
further upfield at approximately 86.0 ppm. These shifts are
similar to other piano-stool Cp* rhodium and iridium
complexes.38–41 The p-cymene moieties of complexes 3 and 6
show two singlets between 82.0 and 83.0 ppm due to the reso-
nances of the unsubstituted aromatic carbons of the ring.
The isopropyl substituted aromatic carbon and the methyl sub-
stituted aromatic carbon resonates at approximately 97.0 and
104.0 ppm respectively. These resonances agree with similar
mononuclear 4-pyridyl complexes.14,33,37
Further analysis of the complexes 3–8 using infrared spec-
troscopy reveals no shift in the absorption band associated
with the CvO bond vibration of the now metalated ligands,
supporting the evidence gleaned from the NMR analyses that
metal coordination to the ester oxygen atoms does not occur.
The CvN bond vibration of the pyridyl functionalities do
exhibit an expected shift to higher frequency as a consequence
of metal complexation to nitrogen. A high frequency increase
in the range of 15–20 cm−1 is noted and is consistent with
similar examples described in the literature.42–45 For all of the
complexes, a strong absorption band in the region of
1200–1300 cm−1 is observed and is assigned to the C–O bond
stretching of the ester functionalities.14,33,36,46
Mass spectral analysis of complexes 3–8 using ESI-MS
reveals molecular ion fragments corresponding to the mole-
cular weights of the proposed structures. Complexes 4 and 7
exhibit base peaks corresponding to the sodium adduct and
Scheme 2
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complexes 3 and 8 form adducts with methanol upon either
protonation or loss of chlorido ligands. Complexes 5 and 6
show m/z peaks corresponding to the loss of a chlorido ligand.
Within these complexes, there are several potential sites of
ionization, thus mass fragments corresponding to multiply
charged species is possible.
Single-crystal X-ray diﬀraction
The molecular structures of complexes 4 and 5 were elucidated
using single-crystal X-ray diﬀraction. Crystals were grown from
a solution of chloroform and hexane. Both complexes crystal-
lize with one complex molecule and two chloroform molecules
in the asymmetric unit with a monoclinic system and P21
space group. Fig. 3 and 4 show the molecular structures of 4
and 5 and Tables 1 and 2 list selected bond lengths and
angles.
The determined molecular structures of complexes 4 and 5
validate the structures of 3–8 evidenced by the spectroscopic
and spectrometric characterisations discussed earlier. In the
structures of both dinuclear complexes, each metal center
adopts a typical ‘piano-stool’ conformation with the two chlo-
rido ligands and the pyridyl ring as the three legs, giving rise to
a pseudo-tetrahedral coordination geometry. The pentamethyl-
cyclopentadienyl ring is bound to the metal in the expected η5
manner. The pyridyl ester ligand is coordinated to each
metal center in a monodentate fashion as suggested by the
spectroscopic data. Comparison of the Rh–C and Ir–C bond
lengths between the metal and each bonded carbon of the
Fig. 3 Molecular structure of complex 4 with hydrogen atoms omitted for clarity.
Fig. 4 Molecular structure of complex 5 with hydrogen atoms omitted for clarity.
Table 1 Selected bond lengths (Å) observed for complexes 4·2CHCl3 and 5·2CHCl3
Complex 4·2CHCl3
M = Rh
Complex 5·2CHCl3
M = Ir
Complex 4·2CHCl3
M = Rh
Complex 5·2CHCl3
M = Ir
M1–N1 2.119(8) 2.095(8) M2–N2 2.116(8) 2.114(8)
M1–C1 2.054(14) 2.160(9) M2–C31 2.137(9) 2.143(10)
M1–C2 2.099(11) 2.161(9) M2–C32 2.143(8) 2.157(10)
M1–C3 2.146(12) 2.162(9) M2–C33 2.169(9) 2.163(11)
M1–C4 2.203(16) 2.132(11) M2–C34 2.154(9) 2.193(12)
M1–C5 2.093(13) 2.130(10) M2–C35 2.139(8) 2.136(11)
M1–Cl1 2.412(2) 2.401(3) M2–Cl3 2.399(2) 2.415(3)
M1–Cl2 2.399(2) 2.415(3) M2–Cl4 2.416(2) 2.394(3)
N1–C11 1.321(12) 1.361(13) N2–C28 1.323(12) 1.344(13)
N1–C15 1.337(11) 1.342(14) N2–C29 1.362(12) 1.379(13)
O1–C16 1.160(12) 1.198(14) O3–C25 1.291(12) 1.312(13)
O2–C16 1.332(13) 1.364(14) O4–C25 1.218(12) 1.196(14)
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pentamethylcyclopentadienyl ring reveal them to be similar
indicating that the ring is symmetrically bound to rhodium (4)
or iridium (5). The bond lengths observed in 4 and 5 between
the metal and the coordinated atoms are approximately 2.40 Å
(M–Cl), 2.10 Å (M–C) and 2.10 Å (M–N). These values agree
with those observed for similar complexes in the litera-
ture16,30,34,40,41,44,45,47 as well as the expected length calculated
from the covalent radii of iridium or rhodium, chlorine (M–Cl:
2.40 (Ir); 2.41 (Rh) Å), carbon (M–C: 2.09 (Ir); 2.10 (Rh) Å) and
nitrogen (M–N: 2.09 (Ir); 2.10 (Rh) Å).48
In the coordinated pyridyl-ester ligand of both complexes
4 and 5, the C–N bond lengths in the pyridyl ring are found to
be between 1.30–1.35 Å. The alkyl C–O bond lengths of the
ester functionalities are between 1.30 and 1.36 Å and the CvO
bond lengths are shorter (1.16–1.20 Å), comparing favourably
to the interatomic distances typical of pyridines and aromatic
esters (CvN: 1.34 Å, C–O: 1.43 Å and CvO: 1.23 Å).49
With respect to the bond angles, the values observed
between Cl–M–Cl and N–M–Cl are all close to 90° and the
bond angles formed between the bonded carbons of the Cp*
ligand, the metal and the chlorido ligand vary from 90 to 150°.
This trend has also been observed within the molecular struc-
tures of similar Cp*Ir(III) and Cp*Rh(III) pyridyl com-
plexes.16,30,34,44,45 Within the pyridyl ester ligands of both 4
and 5, the dihedral angles formed between the central phenyl
ring and each ester functionality is close to 90° indicating that
the pyridyl rings orientate themselves almost perpendicular to
the phenyl spacer thereby minimizing electrostatic interactions
within the complex molecules.
Turbidimetric assay
The solubility of a compound in aqueous-based media is an
important property. Solubility has a bearing on a compound’s
bioavailability, which impacts on absorption, and it also vali-
dates the in vitro assay data obtained. There are three general
categories that compounds can be classified based on their solu-
bility range: (i) <10 μg mL−1 (sparingly soluble), (ii) 10–60 μg
mL−1 (partially soluble) and (iii) >60 μg mL−1 (soluble). If a
compound displays solubility greater than 60 μg mL−1, then it
should have good absorption. One method used to validate
aqueous solubility during early drug discovery is the Turbidi-
metric (kinetic) Solubility Assay.50–53 This assay was used to
evaluate the solubility of compounds 1–8 and the [Ru(p-
cymene)Cl2]2, [Rh(C5Me5)Cl2]2 and [Ir(C5Me5)Cl2]2 dimers in
phosphate buﬀered saline at pH 7.4 (Table 3).
The drugs, reserpine and hydrocortisone were used as con-
trols. In micromolar concentration, ligands 1 and 2, the trinuc-
lear complexes 6–8 and the metal dimers showed no turbidity
up to the highest compound concentration tested (200 μM). All
of the compounds (1–8) displayed solubility greater than 60 μg
mL−1. Overall, the data ascertained suggests that the di- and
tripyridyl ester compounds are good candidates for in vitro bio-
logical testing. Precipitation of these compounds from the
various in vitro assays may be unlikely and thus the activities
observed for these compounds are a true reflection of their
in vitro activity since all of the compounds should remain in
solution.
In vitro biological studies
Since metal-containing compounds have been shown to have
relevant antiparasitic properties,26–29 the in vitro antiparasitic
activity of all compounds was determined against the
Table 2 Selected angles (°) observed for complexes 4·2CHCl3 and 5·2CHCl3
Complex 4·2CHCl3
M = Rh
Complex 5·2CHCl3
M = Ir
Complex 4·2CHCl3
M = Rh
Complex 5·2CHCl3
M = Ir
C4–M1–Cl1 92.8(4) 136.9(4) C34–M2–Cl3 94.4(3) 93.2(3)
C3–M1–Cl1 117.0(3) 101.8(4) C33–M2–Cl3 124.8(3) 109.6(3)
C1–M1–Cl1 138.6(4) 121.5(3) C31–M2–Cl3 135.8(3) 152.3(4)
C2–M1–Cl1 153.0(3) 94.7(3) C32–M2–Cl3 160.4(3) 148.2(3)
C5–M1–Cl1 100.9(4) 158.8(3) C35–M2–Cl3 100.3(3) 112.5(4)
N1–M1–Cl1 88.4(2) 87.2(3) N2–M2–Cl3 89.3(2) 86.0(2)
C4–M1–Cl2 123.7(3) 135.8(4) C34–M2–Cl4 123.7(3) 137.9(4)
C3–M1–Cl2 96.1(3) 161.0(3) C33–M2–Cl4 95.6(3) 103.0(3)
C1–M1–Cl2 131.7(4) 96.7(3) C31–M2–Cl4 133.9(3) 120.7(4)
C2–M1–Cl2 97.0(3) 125.1(3) C32–M2–Cl4 100.4(3) 94.2(3)
C5–M1–Cl2 156.5(4) 101.2(3) C35–M2–Cl4 160.3(3) 159.3(4)
N1–M1–Cl2 88.8(2) 87.0(2) N2–M2–Cl4 87.2(2) 86.7(2)
Cl2–M1–Cl1 89.44(8) 87.31(10) Cl3–M2–Cl4 90.28(9) 86.94(10)
C25–O3–C24–C21 −96.1(10) −92.9(12) C16–O2–C17–C18 −78.5(11) −84.3(12)
Table 3 Turbidimetric solubility data for compounds 1–8
Compound
Determined
turbidimetric
solubility (μM)
Determined
turbidimetric
solubility (μg mL−1)
1 >200 >70
2 >200 >97
3 160–200 154–192
4 160–200 155–193
5 80–120 91–137
6 >200 >280
7 >200 >282
8 >200 >336
[Ru(p-cymene)Cl2]2 >200 >122
[Rh(C5Me5)Cl2]2 >200 >104
[Ir(C5Me5)Cl2]2 >200 >159
Reserpine 20–40 12–24
Hydrocortisone >200 >72
Paper Dalton Transactions
518 | Dalton Trans., 2014, 43, 513–526 This journal is © The Royal Society of Chemistry 2014
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
2 
O
ct
ob
er
 2
01
3.
 D
ow
nl
oa
de
d 
on
 5
/8
/2
01
9 
5:
24
:2
5 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
chloroquine-sensitive (CQS) NF54 P. falciparum strain and the
T. vaginalis strain G3. The IC50 values obtained with standard
error of the mean (SEM) values are shown in Table 4. The
ruthenium, rhodium and iridium dimers, [Ru(p-cymene)Cl2]2,
[Rh(C5Me5)Cl2]2 and [Ir(C5Me5)Cl2]2 and the organometallic
chloroquine analogue, ferroquine, were also screened for
activity at the same time as compounds 1–8. Chloroquine
diphosphate was screened as a control for the in vitro
experiments.
With respect to the free ligands, ligand 2 showed better
activity than 1. All of the transition metal complexes (3–8) dis-
played enhanced activity compared to the corresponding free
ligands. The tripyridyl ester complex 8 (IC50 = 10.27 μM) is
twice as active compared to 2 (IC50 = 22.18 μM) and the tri-
ruthenium complex 6 (IC50 = 5.87 μM) is almost four times
more active than 2. Consideration of the antiplasmodial data
obtained for the dipyridyl ester complexes (3–5) showed that
these complexes were also much more active than their corres-
ponding free ligand 1 (IC50 = 48.42 μM). However, there was a
great diﬀerence in the antiplasmodial activity as the metal
fragment was varied. Complex 3 (IC50 = 7.04 μM) was the most
active, followed by 4 (IC50 = 25.16 μM) and then 5 (IC50 =
42.63 μM) was the least active of the three complexes (3–5). For
the dinuclear complexes it is clear that activity decreased with
a change in metal fragment in the order of Ru(p-cymene)Cl2 >
Rh(C5Me5)Cl2 > Ir(C5Me5)Cl2.
Functionalization of the free ligands (1 and 2) with either
the Ru(p-cymene)Cl2 (3 and 6) or Rh(C5Me5)Cl2 (4 and 7) moi-
eties led to a strong increase in antiplasmodial activity
suggesting that these metal moieties play a role in activity.
When comparing the activities of the dimers [Ru(p-cymene)-
Cl2]2, [Rh(C5Me5)Cl2]2 and [Ir(C5Me5)Cl2]2, to the corres-
ponding ester (3–8) complexes, it can be seen that the dimers
were less active than the di- and trinuclear complexes with the
exception of complex 4. This observation, along with the fact
that the complexes are more active than the free ligands,
advocates that there is a cooperative eﬀect between metal
moiety and ligand on antiplasmodial activity. The ligands
(1 and 2) as well as the dimers were only moderately active indivi-
dually but conjugation of the diﬀerent metal moieties onto the
corresponding ligand yielded a beneficial increase in activity
with an increase in metal moieties leading to an increase in
antiplasmodial activity in vitro. While the results obtained
show that complexes 1–8 are more active than their corres-
ponding ligands, they were not as active as ferroquine (IC50 =
0.03 μM) and chloroquine diphosphate (IC50 = 0.02 μM).
From all of the compounds (1–8) screened for in vitro anti-
plasmodial activity against the NF54 CQS P. falciparum strain,
compounds showing cytotoxicities of approximately 10 μM or
less were assayed for β-hematin inhibition (Table 5). The dimers,
[Ru(p-cymene)Cl2]2, [Rh(C5Me5)Cl2]2 and [Ir(C5Me5)Cl2]2, as
well as the ligands 1 and 2 were also assayed for comparison.
Hemozoin (malaria pigment) formation is currently a target
for antiplasmodial drug discovery. In the life cycle of the
Plasmodium falciparum parasite, the ingestion and degradation of
hemoglobin from the infected host provides essential amino
acids for parasite growth and nutrition.54 A side product of
this process is the formation of free heme that is toxic to the
parasite. In order to prevent the detrimental eﬀects of free
heme, the parasite initiates a detoxification mechanism and
removes the threat by conversion of the free heme into a crys-
talline solid known as hemozoin that is nontoxic to the para-
site. Clinically used drugs, amodiaquine and chloroquine are
believed to inhibit the formation of hemozoin.55 The ability of
a potential drug to inhibit formation of hemozoin can be
measured using the NP-40 mediated β-hematin (synthetic
hemozoin) inhibition assay. NP-40 is a low cost, lipophilic
detergent that can mediate the formation of synthetic hemo-
zoin (β-hematin). The NP-40 mediated assay mimics the con-
ditions of the acidic food vacuole in the parasite to give a
better measure of hemozoin formation.
The tri-ruthenium pyridyl ester complex 6 showed the
highest inhibitory eﬀect (IC50 = 7.76 μM) that was comparable
to amodiaquine (IC50 = 6.83 μM). Neither ligand 1 or 2 was
able to inhibit β-hematin formation, yet their corresponding
Table 4 In vitro IC50
a data for compounds 1–8 against the chloro-
quine-sensitive P. falciparum strain NF54
Compound
Metal
entities
No of
metals
NF54
(μM)
SEMb
(μM)
1 None 0 48.42 0.62
2 None 0 22.18 3.46
3 Ru(p-cymene)Cl2 2 7.04 0.72
4 Rh(C5Me5)Cl2 2 25.16 2.23
5 Ir(C5Me5)Cl2 2 42.63 1.01
6 Ru(p-cymene)Cl2 3 5.87 0.58
7 Rh(C5Me5)Cl2 3 10.84 2.55
8 Ir(C5Me5)Cl2 3 10.27 2.04
[Ru(p-cymene)Cl2]2
c 2 16.80 2.94
[Rh(C5Me5)Cl2]2
c — 2 20.90 0.87
[Ir(C5Me5)Cl2]2
c — 2 59.40 19.45
Ferroquinec — 1 0.03 0.01
Chloroquine diphosphatec — — 0.02 0.01
a Concentration inhibiting 50% of parasite growth. b SEM: standard
error of the mean. c The dimers, FQ and CQDPP were screened for
activity at the same time as 1–8.
Table 5 IC50 data for compounds screened for β-hematin inhibitory
activity using NP-40 mediated β-hematin assaya
Compound IC50 (μM) 95% Confidence interval
1 No inhibition —
2 No inhibition —
3 29.19 28.09–30.34
6 7.76 7.19–8.37
7 24.99 21.47–29.90
8 12.48 11.76–13.24
[Ru(p-cymene)Cl2]2 No inhibition —
[Rh(C5Me5)Cl2]2 No inhibition —
[Ir(C5Me5)Cl2]2 No inhibition —
Ferroquine 14.51 13.72–15.34
Chloroquine 18.43 17.56–19.34
Amodiaquine 6.83 6.57–7.10
aOnly compounds showing in vitro cytotoxic values of approximately
10 μM or less were screened.
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complexes (3 and 6–8) showed inhibitory eﬀects suggesting
that the overall complex structure is needed to stop formation
of synthetic hemozoin. The fact that the dimers did not show
activity also highlights the importance of the interaction
between the metal and ligand for complexes 3 and 6–8.
The tripyridyl ester rhodium complex (7) displayed moder-
ate inhibition (IC50 = 24.99 μM) while the iridium derivative (8)
was more active (IC50 = 12.48 μM). Both these complexes were
better at inhibiting formation of synthetic hemozoin than
ferroquine and chloroquine; drugs that target hemozoin
formation within the malaria parasite.29
All of the compounds screened using the NP-40 mediated
assay contain several aromatic rings making them capable of
intermolecular π–π interactions. It is possible that these com-
pounds can inhibit formation of hemozoin through π–π stack-
ing with hematin. All of the ester complexes (3 and 6–8)
screened were able to inhibit β-hematin formation in a lipidic
atmosphere to some degree. It is interesting to note that while
these complexes are only moderately active against the para-
site, they are better inhibitors of hemozoin formation com-
pared to known inhibitors. This property demonstrates that
PGM polyester complexes do have potential as antiparasitics.
Slight structural modifications could yield complexes with
better in vitro activity.
All of the compounds were evaluated for inhibitory activity
against the human parasite T. vaginalis strain G3 (Fig. 5). Cells
were inoculated with either 50 or 25 μM doses of compounds.
All of the compounds were able to influence parasite viability
in a dose-dependent manner.
At 50 μM, the tripyridyl ester ligand (2) displayed higher
inhibitory activity (62.1%) than the dipyridyl ester ligand 1
(42.4%) but a decrease in compound concentration to 25 μM
resulted in ligand 2 displaying a much lower activity than 1
(38.8 vs. 51.1%). At both 25 and 50 μM concentrations, the
dinuclear ruthenium (3) and iridium (5) complexes exhibited
better activities than the dinuclear rhodium complex 4. At
25 μM, complexes 3 and 5 were not as active (24.5 and 19.1%
respectively) as their corresponding free ligand 1 (51%). The
iridium derivative 5 is more active than the free ligand at both
concentrations (65.3% at 25 μM and 74.2% at 50 μM). The tri-
nuclear complexes 7 and 8 displayed better inhibitory activity
compared to the free ligand 2 at both 25 and 50 μM concen-
trations. At 50 μM, the tri-ruthenium complex 6 showed
similar inhibition (44.7%) to ligand 2 (42.4%) but is less active
than 2 at 25 μM (51% vs. 34%). Complex 8 exhibited the best
activity out of all the pyridyl ester complexes tested at both
compound concentrations. At 25 μM, the iridium complexes
(5 and 8) exhibit similar inhibitory activities of 65.3 and 67.3%
respectively. Complexes 3 and 4 display the weakest activity out
of all the compounds.
Overall, complex 8 displayed the best inhibitory eﬀect out
of all complexes tested. None of the compounds were as
potent as metronidazole which is the current FDA approved
treatment for T. vaginalis. This drug displayed 100 percent
inhibition at both concentrations.
The antiproliferative activity of compounds (1–8) were evalu-
ated on the A2780 (cisplatin-sensitive) and A2780cisR (cisplatin-
resistant) human ovarian carcinoma cell lines. The toxicity of
these compounds on non-tumorous cells was also assessed using
the human embryonic kidney (HEK) cell line. Cells were incu-
bated with each compound at diﬀerent concentrations up to a
maximum concentration of 200 μM. The IC50 determinations
are shown in Table 6 and a graphical representation of the
most active compounds’ is depicted in Fig. 6.
The dinuclear iridium complex 5 and the trinuclear com-
plexes (6–8) were the only compounds to show antiproliferative
activity implying that the role played by the number of
aryl ester groups and the type of metal moiety in the complex
Fig. 5 Graphical representation of % inhibition data ascertained for
compounds 1–8 against T. vaginalis strain G3.
Table 6 IC50
a determinations for compounds 1–8 against cisplatin sensitive (A2780) and cisplatin resistant (A2780cisR) human ovarian carcinoma
and Human Embryonic Kidney (HEK) cell linesb
Compound Metal moiety
No of metal
moieties A2780 (μM) A2780cisR (μM) HEK (μM)
1 None 0 >200 >200 >200
2 None 0 >200 >200 >200
3 (p-Cymene)RuCl2 2 >200 >200 >200
4 Cp*RhCl2 2 >200 >200 >200
5 Cp*IrCl2 2 101.9 (8.2) >200 118.8 (99.8)
6 (p-Cymene)RuCl2 3 53.0 (3.0) 84.4 (5.2) 98.1 (2.0)
7 Cp*RhCl2 3 52.4 (0.4) 58.7 (4.1) 68.9 (6.4)
8 Cp*IrCl2 3 97.0 (4.0) 45.5 (5.7) 148.5 (24.7)
Cisplatin — 1 1.5 25 7
a IC50: concentration inhibiting 50% of cell growth.
b Error values are given in parentheses.
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influences inhibitory activity. Complexes 6 and 7 showed
comparable activity to each other (IC50 = 53.0 and 52.4 μM
respectively) in the A2780 cell line. The di- and trinuclear
iridium complexes 5 (IC50 = 101.9 μM) and 8 (IC50 = 97.0 μM)
also displayed similar weak activities.
All of the active complexes (5–8) were less toxic to non-tumor-
ous cells with the tri-iridium complex 8 showing the greatest
diﬀerence in toxicities between the carcinoma cells (A2780 and
A2780cisR) and non-tumorous cells (HEK). Complexes 5–8 were
also less toxic than cisplatin toward the HEK cell line. Complex 8
was more active against the A2780cisR cell line (IC50 = 45.5 μM)
than the A2780 cell line whereas the ruthenium complex 6 was
less active on the A2780cisR cell line (IC50 = 84.4 μM) compared
to the A2780 cell line (IC50 = 53.0 μM). None of the complexes
are as active as cisplatin against either cancer cell line (IC50 =
1.5 μM for A2780 and 25 μM for A2780cisR cells). The ruthe-
nium (6) and rhodium (7) complexes have a better anti-
proliferative eﬀect than the iridium complex 8. Complex 7
displayed the highest cytotoxicity against both cell lines com-
pared to 6 and 8 and it is the least cytotoxic to healthy cells.
It has been demonstrated that the dinuclear complexes
(3–5) are not as active as the trinuclear complexes, implying
that increasing the size and the number of metal centers of
the overall complex increases antitumor activity. This eﬀect
has also been observed for other multinuclear arene–ruthe-
nium complexes.22,35,56 The study of other di-, tri-, tetra- and
hexanuclear ruthenium arene complexes for in vitro cytotoxic
activity against the A2780 and A2780cisR cell lines has been
reported.22,56–59 Most of these complexes demonstrated better
activities than all of the complexes screened during this
study (3–8). However, it is important to note that the com-
plexes reported in the literature contain ligands that are not
structurally similar to the pyridyl ester (1 and 2) ligands used
to prepare 3–8 and in some cases the coordination mode of
the ligands to the metal are diﬀerent to that of complexes 3–8.
In some of the reported complexes, the ligands chelate to the
metal in a bidentate fashion.
Furthermore, all of the compounds (1–8) must be screened
for anti-tumor activity on a panel of other tumor cell lines. It is
possible that these compounds may selectively inhibit growth
of other tumor cell lines.
Conclusions
A new series of di- (3–5) and trinuclear (6–8) complexes con-
taining polypyridyl ester ligands have been prepared. All of the
compounds were isolated as air- and moisture-stable solids
and were characterised using a variety of analytical and spec-
troscopic techniques. The molecular structures of 4 and 5
confirm the monodentate coordination of the pyridyl ester
ligands to each metal shown by the spectroscopic and spectro-
metric characterisations of complexes 3–8. The elucidated
molecular structures of the complexes 4 and 5 revealed a
typical ‘piano-stool’ geometry around the metal and analysis of
the dihedral angles formed between the central phenyl ring
and the ester functionalities indicate that the pyridyl metal
moieties position themselves almost perpendicular to the
phenyl spacer thus minimizing electrostatic interactions.
All of the complexes and their free ligands (1–8) were found
to exhibit moderate to high antiplasmodial activity against the
NF54 CQS P. falciparum strain. The trinuclear complexes (6–8)
display better activities compared to the dinuclear derivatives
thus proposing that an increase in metal moieties leads to an
increase in antiplasmodial activity in vitro. All of the complexes
showed better activity than the corresponding free ligand.
The most active compounds were assayed for inhibition of
β-hematin formation and all of the complexes tested inhibited
formation of synthetic hemozoin. Against Trichomonas vaginalis
strain G3, complex 8 displayed the best inhibitory eﬀect out of
all complexes tested.
Antitumoral studies against the A2780 and A2780cisR cell
lines revealed that the trinuclear pyridyl ester complexes were
the only complexes to display activity up to the highest concen-
tration tested. The tri-iridium complex (8) demonstrated the
lowest toxicity against human embryonic kidney (HEK) cells.
The moderate activity of these complexes could be improved
through modification of the ligand structure and/or the metal
moieties. The design of pyridyl ester ligands that can chelate
to the metal in a polydentate manner may lead to the
formation of complexes that are more stable and hence display
better pharmacological activities. Modification of the arene or
cyclopentadienyl ligands of the metal moieties to increase
hydrophilicity could also enhance activity.
Experimental
Materials and equipment
1,2,3,4,5-Pentamethylcyclopentadiene, α-phellandrene, 4-bromo-
methylpyridine hydro-bromide, isonicotinic acid, 1,3,5-ben-
zenetricarboxylic acid and 1,4-bis(bromomethyl)benzene were
purchased from Sigma-Aldrich and used without further puri-
fication. Ruthenium trichloride trihydrate, rhodium trichlo-
ride trihydrate and iridium trichloride trihydrate were kindly
donated by AngloAmerican Platinum Limited. All solvents
used were analytical grade and dried over molecular sieves. All
reactions were carried out in air unless otherwise stated.
The precursors, [Ru(p-cymene)Cl2]2,
60 [Rh(C5Me5)Cl2]2
61 and
Fig. 6 Graphical representation showing the cytotoxicity against the
A2780, A2780cisR and HEK cell lines.
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[Ir(C5Me5)Cl2]2
61 were synthesised using literature methods.
The synthesis of ligands 162 and 263 has been previously
reported.
Nuclear Magnetic Resonance (NMR) Spectra were recorded
on a Varian Unity XR400 MHz (1H at 399.95 MHz, 13C at
100.58 MHz), Varian Mercury XR300 (1H at 300.08 MHz, 13C at
75.46 MHz) or Bruker Biospin GmbH (1H at 400.22 MHz, 13C
at 100.65 MHz) spectrometer at ambient temperature. Chemi-
cal shifts for 1H and 13C{1H} NMR shifts are reported using
tetramethylsilane (TMS) as the internal standard and 31P{1H}
NMR spectra were measured relative to H3PO4 as the external
standard. NMR spectra were recorded in deuterated chloro-
form (CDCl3-d1) unless otherwise stated. Infrared (IR) absorp-
tions were measured on Perkin-Elmer Spectrum 100 FT-IR
Spectrometer using a Universal Diamond Attenuated Total
Reflection (ATR) accessory. Melting points were determined
using a Büchi Melting Point Apparatus B-540. Mass Spectro-
metry determinations were carried out on all new com-
pounds using electrospray ionisation (ESI) on a Waters API
Quattro Micro instrument in either the positive or negative
mode. All final compounds were analysed by HPLC using an
Xbridge C18 (4.6 × 150 mm) 5 μm column; 2.0 µL injection
volume; flow 0.7 mL min−1; gradient: 30–100% B in 15 min
(hold 2 min) (Mobile phase A: 10 nM NH4OAc in H2O and
Mobile phase B: 10 nM NH4OAc in methanol) with a Thermo
Separation Products (TSP), Spectra SERIES P200 pump UV100
detector set at 254 nm.
General synthetic method for dinuclear complexes
The ligand (1) (1 molar equivalent) was dissolved in DCM
(15 cm3) and the appropriate ruthenium, rhodium or iridium
dimer (1.1 molar equivalent) was added and the reaction solu-
tion was stirred for 16 hours at room temperature. The reac-
tion solvent was then reduced to approximately a third of its
original volume. The product was then precipitated from solu-
tion by addition of diethyl ether and isolated by vacuum fil-
tration, washed with diethyl ether and dried.
Complex 3. Diisonicotinic acid 1,4-xylylene diester (1)
(0.0536 g, 0.154 mmol) was reacted with [Ru(p-cymene)Cl2]2
(0.101 g, 0.163 mmol). The product (3) was isolated as dark
red amorphous solid. Yield: 0.148 g, 97%. Mp: 226–228 °C,
decomposition without melting). 1H NMR (400 MHz, CDCl3-d1):
δ (ppm) = 9.24 (d, 3J (H–H): 6.41 Hz, 4H, py), 7.85 (d, 3J (H–H):
6.59 Hz, 4H, py), 7.46 (s, 4H, Ar), 5.46 (d, 3J (H–H): 5.68 Hz,
4H, Ar), 5.41 (s, 4H, O–CH2), 5.24 (d,
3J (H–H): 5.86 Hz, 4H, Ar),
3.00–2.96 (m, 2H, Ar–CH(CH3)2), 2.10 (s, 6H, Ar–CH3), 1.32 (d,
3J (H–H): 6.96 Hz, 12H, Ar–CH(CH3)2).
13C NMR (400 MHz,
CDCl3-d1): δ (ppm) = 163.6 (CvO), 155.9 (py), 138.5 (py), 135.5
(Ar), 128.8 (Ar), 123.5 (py), 103.8 (Ar), 97.4 (Ar), 83.1 (Ar), 82.4
(Ar), 67.5 (O–CH2), 30.7 (Ar–CH(CH3)2), 22.3 (Ar–CH(CH3)2),
18.2 (Ar–CH3). IR (atr, cm
−1) ν = 1719 (s, CvO), 1611 (s, CvN),
1271 (s, vC–O–CH2–). ESI-MS: m/z 312.01 ([M − 3Cl +
3CH3OH]
3+, 100%). HPLC: tR = 13.9 min.
Complex 4. Diisonicotinic acid 1,4-xylylene diester (1)
(0.0538 g, 0.154 mmol) was reacted with [Rh(C5Me5)Cl2]2
(0.0954 g, 0.154 mmol). The product (4) was isolated as a
bright orange amorphous solid. Yield: 0.141 g, 92%. Mp:
169–171 °C, decomposition without melting. 1H NMR
(400 MHz, CDCl3-d1): δ (ppm) = 9.16 (br s, 4H, py), 7.92 (d,
3J (H–H): 6.59 Hz, 4H, py), 7.47(s, 4H, Ar), 5.42 (s, 4H, O–CH2),
1.59 (s, 30H, Cp*). 13C NMR (400 MHz, CDCl3-d1): δ (ppm) =
163.8 (CvO), 154.0 (py), 138.7 (py), 135.6 (Ar), 128.77 (Ar),
124.1 (py), 94.2 (Cp*), 67.4 (O–CH2), 8.9 (Cp*). IR (atr, cm
−1)
ν = 1739 (s, CvO), 1613 (s, CvN), 1278 (s, vC–O–CH2–).
ESI-MS: m/z 989.02 ([M − H + Na]+, 100%). HPLC: tR =
13.8 min.
Complex 5. Diisonicotinic acid 1,4-xylylene diester (1)
(0.0426 g, 0.122 mmol) was reacted with [Ir(C5Me5)Cl2]2
(0.101 g, 0.127 mmol). The product (5) was isolated as a bright
yellow amorphous solid. Yield: 0.136 g, 92%. Mp: 295–296 °C.
1H NMR (400 MHz, CDCl3-d1): δ (ppm) = 9.17 (d,
3J (H–H): 6.78
Hz, 4H, py), 7.90 (d, 3J (H–H): 7.99 Hz, 4H, py), 7.48 (s, 4H, Ar),
5.43 (s, 4H, O–CH2), 1.55(s, 30H, Cp*).
13C NMR (400 MHz,
CDCl3-d1): δ (ppm) = 163.4 (CvO), 154.4 (py), 138.7 (py), 135.6
(Ar), 128.8 (Ar), 124.5 (py), 86.1 (Cp*), 67.5 (O–CH2), 8.5 (Cp*).
IR (atr, cm−1) ν = 1739 (s, CvO), 1613 (s, CvN), 1278 (s, vC–
O–CH2). ESI-MS: m/z 1100.21 ([M − Cl]+, 100%). HPLC: tR =
13.8 min.
General synthetic method for trinuclear complexes
The ligand (2) (2 molar equivalent) was dissolved in DCM
(15 cm3) and the appropriate ruthenium, rhodium or iridium
dimer (3.1 molar equivalent) was added and the reaction solu-
tion was stirred for 16 hours at room temperature. The reac-
tion solvent was then reduced to approximately a third of its
original volume. The product was then precipitated from solu-
tion by addition of diethyl ether and isolated by vacuum fil-
tration, washed with diethyl ether and dried.
Complex 6. Benzene-1,3,5-tricarboxylic acid tripyridin-
4-ylmethyl ester (2) (0.0519 g, 0.107 mmol) was reacted with
[Ru(p-cymene)Cl2]2 (0.106 g, 0.174 mmol). The product (6) was
isolated as a yellow brown amorphous solid. Yield: 0.109 g,
70%. Mp: 215–216 °C. 1H NMR (400 MHz, CDCl3-d1): δ (ppm) =
9.03 (d, 3J (H–H): 6.41 Hz, 6H, py), 8.80 (s, 3H, Ar), 7.35 (d,
3J (H–H): 6.41 Hz, 6H, py), 5.47 (d, 3J (H–H): 5.86 Hz, 6H, Ar),
5.43 (s, 6H, O–CH2), 5.27 (d,
3J (H–H): 6.04 Hz, 6H, Ar),
2.80–3.10 (m, 3H, Ar–CH(CH3)2), 2.09 (s, 9H, Ar–CH3), 1.31 (d,
3J (H–H): 6.96 Hz, 18H, Ar–CH(CH3)2).
13C NMR (400 MHz,
CDCl3-d1): δ (ppm) = 163.8 (CvO), 155.1 (py), 146.6 (Ar), 135.1
(Ar), 130.8 (py), 123.0 (py), 103.6 (Ar), 97.2 (Ar), 82.8 (Ar), 82.2
(Ar), 64.7 (O–CH2), 30.7 (Ar–CH3), 22.3 (Ar–CH(CH3)2), 18.2
(Ar–CH(CH3)2). IR (atr, cm
−1) ν = 1728 (s, CvO), 1617 (s,
CvN), 1232 (s, vC–O–CH2–). ESI-MS: m/z 1367.03 ([M − Cl]+,
20%); 312.01 ([M − 4Cl]4+, 100%). HPLC: tR = 13.5 min.
Complex 7. Benzene-1,3,5-tricarboxylic acid tripyridin-
4-ylmethyl ester (2) (0.0513 g, 0.106 mmol) was reacted with
[Rh(C5Me5)Cl2]2 (0.101 g, 0.163 mmol). The product (7) was
isolated as dark orange amorphous solid. Yield: 0.132 g, 88%.
Mp: 209–210 °C. 1H NMR (400 MHz, CDCl3-d1): δ (ppm) = 9.00
(br s, 6H, py), 8.89 (s, 3H, Ar), 7.43 (d, 3J (H–H): 6.59 Hz, 6H,
py), 5.48 (s, 6H, O–CH2), 1.59 (s, 45H, Cp*).
13C NMR
(300 MHz, DMSO-d6): δ (ppm) = 163.9 (CvO), 153.6 (py), 146.9
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(Ar), 135.2 (Ar), 130.8 (py), 123.6 (py), 94.22 (Cp*), 64.7 (O–
CH2), 8.9 (Cp*). IR (KBr, cm
−1) ν = 1723 (s, CvO), 1616 (m,
CvN), 1225 (s, –C–O–CH2–). ESI-MS: m/z 1432.01 ([M − H +
Na]+, 100%). HPLC: tR = 13.5 min.
Complex 8. Benzene-1,3,5-tricarboxylic acid tripyridin-
4-ylmethyl ester (2) (0.0397 g, 0.0821 mmol) was reacted with
[Ir(C5Me5)Cl2]2 (0.100 g, 0.125 mmol). The product (8) was iso-
lated as a bright yellow amorphous solid. Yield: 0.113 g, 82%.
Mp: 227–230 °C, decomposition without melting. 1H NMR
(400 MHz, CDCl3-d1): δ (ppm) = 9.01 (d, 6H,
3J (H–H): 6.78 Hz,
py), 8.90, (s, 3H, Ar), 7.42 (d, 3J (H–H): 6.78 Hz, 6H, py), 5.43 (s,
6H, O–CH2), 1.47 (s, 45H, Cp*).
13C NMR (300 MHz, DMSO-d6):
δ (ppm) = 163.9 (CvO), 153.6 (py), 146.9 (Ar), 135.2 (Ar),
130.8 (py), 123.8 (py), 85.9 (Cp*), 64.6 (O–CH2), 8.6 (Cp*).
IR (KBr, cm−1) ν = 1729 (s, CvO), 1612 (m, CvN), 1230 (s,
–C–O–CH2–). ESI-MS: m/z 363.05 ([M + 5H + 4CH3OH]
+, 100%).
HPLC: tR = 13.3 min.
X-Ray structure analysis
Single-crystal X-ray diﬀraction data were collected on a Bruker
KAPPA APEX II DUO diﬀractometer using graphite-monochro-
mated Mo-Kα radiation (χ = 0.71073 Å). Data collection was
carried out at 173(2) K. Temperature was controlled by an
Oxford Cryostream cooling system (Oxford Cryostat). Cell
refinement and data reduction were performed using the
program SAINT.64 The data were scaled and absorption correc-
tion performed using SADABS.42 The structure was solved by
direct methods using SHELXS-9765 and refined by full-matrix
least-squares methods based on F2 using SHELXL-9765 and
using the graphics interface program X-Seed.66,67 The pro-
grams X-Seed and POV-Ray68 were both used to prepare mole-
cular graphic images.
For complex 4, there are four chloroform molecules in the
asymmetric unit. Two of them were modelled with the chlorine
atoms disordered over two positions with each having site
occupancy 0.50. All non-hydrogen atoms of the main molecule,
except the carbon atoms C1A–C10A and C36B–C40B, were
refined anisotropically. C1A–C10A and C36B–C40B were
refined with isotropic temperature factors and were restrained
to a reasonable geometry. All hydrogen atoms were placed in
idealised positions and refined with geometrical constraints.
The structure was refined to R factor of 0.072. The highest
peak is 2.89 e Å−3, 0.92 Å from Rh2B and the deepest hole is
−0.71 e Å−3, 0.57 Å from CL4X. The Flack x parameter was
refined with BASF and TWIN commands to be 0.54936 with
esd 0.03821.
For complex 5, there are four chloroform molecules in the
asymmetric unit. Two of them were modelled with the chlorine
atoms disordered over two positions with each having site
occupancy 0.50. All non-hydrogen atoms of the main molecule,
except the carbon atoms C6A–C10A and C6B–C10B, were
refined anisotropically. C6A–C10A and C6B–C10B were refined
with isotropic temperature factors and were restrained to a
reasonable geometry. All hydrogen atoms were placed in ideal-
ised positions and refined with geometrical constraints. The
structure was refined to R factor of 0.0360. The highest peak is
3.12 e Å−3, 0.86 Å from IR1A and the deepest hole is −1.30 e
Å−3, 0.56 Å from CL1Z. Crystal data and structure refinement
parameters are listed in Table 7.
P. falciparum in vitro assay
The test samples were tested in triplicate on one occasion
against chloroquine-sensitive (CQS) NF54 strain of Plasmodium
falciparum. Continuous in vitro cultures of asexual erythrocyte
stages of P. falciparum were maintained using a modified
method.69 Quantitative assessment of antiplasmodial activity
in vitro was determined via the parasite lactate dehydrogenase
assay using a modified method.70 The test samples were pre-
pared to a 20 mg cm−3 stock solution in 100% DMSO and soni-
cated to enhance solubility. Stock solutions were stored at
−20 °C. Further dilutions were prepared on the day of the
experiment. Chloroquine (CQ) was used as the reference drug
in all experiments. A full dose–response was performed for all
compounds to determine the concentration inhibiting 50% of
parasite growth (IC50-value). Test samples were tested at a
starting concentration of 100 μg cm−3, which was then serially
diluted 2-fold in complete medium to give 10 concentrations;
with the lowest concentration being 0.2 μg cm−3. The same
dilution technique was used for all samples. CQ was tested at a
starting concentration of 100 ng cm−3 against the CQR strain
and 1000 ng cm−3 against the CQS strain. The highest concen-
tration of solvent to which the parasites were exposed to had
no measurable eﬀect on the parasite viability (data not
shown). The IC50-values were obtained using a non-linear
dose–response curve fitting analysis via Graph Pad Prism v.4.0
software.
T. vaginalis in vitro susceptibility assay
Trichomonas vaginalis strain G3 was cultured anaerobically in
15 mL conical centrifuge tubes containing 10 mL of
Table 7 Crystal data for 4·2CHCl3 and 5·2CHCl3
Complex 4·2CHCl3 Complex 5·2CHCl3
Formula C42H48Cl10N2O4Rh2 C42H48Cl10Ir2N2O4
Formula weight 1205.14 1383.72
Crystal system Monoclinic Monoclinic
Space group P21 P21
a (Å) 11.5800(6) 11.572(2)
b (Å) 20.4163(11) 20.505(4)
c (Å) 21.4575(11) 21.518(4)
β (°) 102.7920(10) 103.65(3)
V (Å3) 4947.1(4) 4961.9(17)
Z 4 4
Dc (g cm
−3) 1.618 1.852
µ (mm−1) 1.249 5.938
θ range for data collection (°) 1.80 to 27.56 1.84 to 27.46
Limiting indices −15 < h < 7 0 < h < 14
−26 < k < 26 0 < k < 26
−23 < l < 27 −27 < l < 27
No. of reflns meads 36 455 11 634
No. of reflns used (Rint) 22 713 10 862
No. of params 1001 1021
R1 0.1052 0.0404
wR2 0.2009 0.0942
Goodness of fit on F2 1.023 1.040
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Diamond’s TYM media, pH 6.2. Dimethyl sulfoxide was used
to dissolve compounds and generate 100 mM stock concen-
trations of each compound. Each compound was then tested
at two concentrations, 25 μM and 50 μM, for in vitro inhibition
of parasite growth. DMSO alone controls as well as tubes of
untreated cells were carried along side-by-side. Test cultures
were incubated for 24 hours at 37 °C under anaerobic con-
ditions. Cell densities were determined using a hemacyt-
ometer. Percentage inhibition was determined by comparing
cell numbers in treatment tubes with the DMSO control tube.
The results of these assays (n = 6) were analyzed and standard
errors were determined.
A2780 and A2780cisR cancer in vitro assay
The human A2780 and A2780cisR ovarian carcinoma cells
were obtained from the European Collection of Cell Cultures
(Salisbury, UK). Cells in the log phase of growth were seeded
at a density of 2000–2500 per well into 96-well culture treated
plates in 0.1 mL of complete media in all wells except for one
column reserved for the media only control. The cells were
allowed to attach during an overnight incubation at 37 °C,
5% CO2 prior to treating with test compounds. Test com-
pounds were serially diluted in complete culture media and
added to each well in a volume of 0.1 mL for a total final
volume of 0.2 mL per well (max 0.1% DMSO final, where
used). Cells were exposed to test compounds for 72 hours at
37 °C, 5% CO2. Then, 0.02 mL of MTT reagent was added to
each well and the plates were returned to the incubator for
2 h. After the incubation period, the culture supernatant was
carefully removed from all wells of each plate and DMSO
(0.1 mL) was added to all wells to dissolve the formazan crys-
tals. The plates were allowed to shake on a table shaker at
room temperature for 15 min and the absorbance at 590 nm
was measured using a SpectraMAX e5 plate reader (Molecular
Devices). The percentage of surviving cells was calculated
from the ratio of absorbance of treated to untreated cells. The
IC50 values for the inhibition of cell growth were determined
by fitting the plot of the log of the ratio between the percen-
tages of surviving cells, divided by the amount of dead cells,
against the log of drug concentration using a linear threshold
function.
Detergent mediated assay for β-hematin inhibitors
The β-hematin formation assay method described by Carter
et al.55 was modified for manual liquid delivery. Stock solu-
tions of the test compounds were prepared at 10 mM, 2 mM
and 0.4 mM by dissolving each sample in DMSO with soni-
cation. Test compounds were delivered to a 96 well plate in
triplicate from 0–500 μM (final concentration) with a total
DMSO volume of 10 μL in each well. Deionized H2O (70 μL)
and NP-40 (20 μL; 30.55 μM) were then added. A 25 mM
hematin stock solution was prepared by sonicating hemin in
DMSO, for complete dissolution, and then suspending
177.76 μL of this in a 2 M acetate buﬀer (pH 4.8). The hom-
ogenous suspension (100 μL) was then added to the wells to
give final buﬀer and hematin concentrations of 1 M and
100 μM respectively. The plate was covered and incubated at
37 °C for 16 hours in a water bath. Analysis of the assay was
carried out using the pyridine-ferrichrome method developed
by Ncokazi and Egan.71 A solution of 50% (v/v) pyridine, 30%
(v/v) H2O, 20% (v/v) acetone and 0.2 M HEPES buﬀer (pH 7.4)
was prepared and 32 μL added to each well to give a final pyri-
dine concentration of ±5% (v/v). Acetone (60 μL) was then
added to assist with hematin dispersion. The UV-vis absor-
bance of the plate wells was read on a SpectraMax plate reader.
Sigmoidal dose–response curves were fitted to the absorbance
data using GraphPad Prism v5.00.
Turbidimetric solubility assay
Preparation of 0.01 M pH 7.4 Phosphate Buﬀered Saline (PBS)
involved dissolving 1 intact PBS buﬀer tablet (EC Diagnostics
AB, Sweden) in suﬃcient distilled water to make 1000 mL of a
solution comprising 0.14 M NaCl, 0.003 M KCl and 0.01 M
phosphate buﬀer. This solution was filtered through a 0.22 μm
nylon filter to remove any particulate contaminants and the
pH ascertained using a pH meter. The test compounds were
prepared by making 10 mM stock solutions in DMSO from
which, dilutions of the compounds in both DMSO and 0.01 M
pH 7.4 PBS were prepared in a 96-well plate, in triplicate. Wells
in columns 1–6 contained compounds in DMSO and columns
7–12 contained the compounds in PBS at similar nominal con-
centrations as those in DMSO. The final volume of solvent in
each assay plate well was 200 μL, prepared by pipetting 4 μL
each of solution from the pre-dilution plate to the corres-
ponding well into both DMSO and PBS (both 196 μL). This
ensured that the final concentration of DMSO in the PBS
aqueous buﬀer did not exceed 2% v/v. The diﬀerent concen-
trations in DMSO were prepared to serve as controls to deter-
mine potential false turbidimetric absorbance readings arising
from the compounds in solution absorbing incident radiation
at the analysis wavelength. After making the assay plate prepa-
ration, the plate was covered and left to equilibrate for 2 hours
at ambient temperature. After incubation, UV-vis absorbance
readings from the plate were measured at 620 nm. Corrected
absorbance readings at diﬀerent concentrations of test com-
pounds were calculated by subtracting absorbance of the
blank (DMSO and 1% DMSO in PBS) from each subsequent
concentration absorbance.
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